SCHEMBL1331464

SCHEMBL1331464

Cc1cccc(NC(=O)Nc2ccc(-c3ccc4c(-c5cnn(C[C@@H](C)O)c5)n[nH]c4c3)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.62
FGFR1 P11362 9/20 0.60
DDR2 Q16832 6/20 0.60
KIT P10721 8/20 0.56
CSF1R P07333 8/20 0.56
FLT1 P17948 7/20 0.56
FLT3 P36888 6/20 0.56
AURKA O14965 6/20 0.56
ROCK1 Q13464 5/20 0.56
NTRK1 P04629 5/20 0.56
LCK P06239 5/20 0.56
ROCK2 O75116 5/20 0.56
RPS6KA3 P51812 5/20 0.56
AURKB Q96GD4 5/20 0.56
RPS6KB1 P23443 4/20 0.56
STK3 Q13188 4/20 0.56
PLK3 Q9H4B4 4/20 0.56
FYN P06241 4/20 0.56
LYN P07948 4/20 0.56
BLK P51451 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28804745 0.90 FGFR1 (0.56) KDRFGFR1DDR2KITCSF1R
SCHEMBL28804742 0.90 FGFR1 (0.56) KDRFGFR1DDR2KITCSF1R
SCHEMBL1331637 0.88 KDR (0.64) KDRFGFR1DDR2KITCSF1R
SCHEMBL1332041 0.85 KDR (0.69) KDRFGFR1DDR2KITCSF1R
SCHEMBL1331362 0.83 FGFR1 (0.62) KDRFGFR1DDR2KITCSF1R
SCHEMBL1330486 0.81 KDR (0.62) KDRFGFR1DDR2KITCSF1R
SCHEMBL1330072 0.80 KDR (0.75) KDRFGFR1KITCSF1RFLT1
SCHEMBL1331406 0.79 FGFR1 (0.58) KDRFGFR1DDR2KITCSF1R
SCHEMBL1331714 0.79 KDR (0.70) KDRFGFR1KITCSF1RFLT1
SCHEMBL1330644 0.78 FGFR1 (0.57) KDRFGFR1DDR2KITCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569301-A1 INDAZOLE INHIBITORS OF KINASE Abbvie Inc. (US) 2013-03-20 EP disclosed
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
WO-2011143430-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 WO disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB KDR 11/4885FGFR1 227/4885DDR2 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.